grant

Stargardt/ABCA4 disease in African Americans

Organization COLUMBIA UNIVERSITY HEALTH SCIENCESLocation NEW YORK, UNITED STATESPosted 1 Jul 2024Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2025Accuracy of DiagnosisAddressAdmixtureAffectAfrican AmericanAfrican American groupAfrican American individualAfrican American peopleAfrican American populationAfrican AmericansAfro AmericanAfroamericanAgeAllelesAllelomorphsClinicalClinical DataClinical TrialsCodeCoding SystemCounselingCoupledDataDedicationsDiseaseDisorderEuropeanFamilial juvenile macular degeneration syndromeFamilyFunctional RNAFutureGenesGeneticGenetic DiversityGenetic ScreeningGenetic VariationGenomeGenotypeJuvenile onset macular degenerationLinkMinorityMolecular Modeling Nucleic Acid BiochemistryMolecular Modeling Protein/Amino Acid BiochemistryMolecular ModelsNoncoding RNANontranslated RNAOnset of illnessOrganoidsOutcome StudyPathogenicityPatient CarePatient Care DeliveryPatient RecruitmentsPatientsPersonsPhenocopyPhenotypePigmentary RetinopathyPopulationRacial GroupResearchRetinaRetinal DiseasesRetinal DisorderRetinitis PigmentosaSTGD3STGD3 diseaseSeveritiesStargardt diseaseStargardt macular dystrophyStargardt syndromeStargardt's diseaseStargardt-3Stargardt-3 macular dystrophyStargardt-like macular dystrophyStatistical Data AnalysesStatistical Data AnalysisStatistical Data InterpretationStructural ModelsStructureTapetoretinal DegenerationTestingUnited StatesUntranslated RNAVariantVariationagescare for patientscare of patientscaring for patientsclinical heterogeneityclinical phenotypeclinical prognosiscohortcone-rod dystrophydesigndesigningdiagnostic accuracydisease diagnosisdisease onsetdisease subgroupsdisease subtypedisorder onsetdisorder subtypeexomefundus flavimaculatusgenetic analysisgenetic approachgenetic strategyiPSiPSCiPSCsimprovedin vitro Assayinduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinsightmolecular modelingmouse modelmurine modelnoncodingparticipant recruitmentprognosticprogramsprotein expressionprotein functionracial populationracial subgrouprecruitretina diseaseretina disorderretinopathyrod and cone dystrophyrod-cone dystrophysegregationstatistical analysistranslational studyunder served minorityunderserved minority
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project summary/Abstract
Disease-associated variation in the ABCA4 gene has emerged as the most prevalent cause of Mendelian

retinal disease affecting an estimated 50,000 people in the United States. The extensive clinical heterogeneity

of ABCA4-associated retinopathy, in short ABCA4-RD, which includes >40 clinical phenotypes entities (most

often called Stargardt disease (STGD1), cone-rod dystrophy (CRD), retinitis pigmentosa (RP)-like, etc.),

reflects its equally large genotypic profile with >2300 known disease-associated variants. While the clinical and

genetic spectrum of patients of European descent has been advanced significantly since the discovery of the

ABCA4 gene in 1997, the same is practically unknown for underserved minorities, especially for patients of

African American (AA) descent. Only two studies have been performed in small cohorts of AA patients;

therefore, the absolute majority remain uncharacterized. Therefore, it is clearly necessary to fill this serious

void by comprehensive, integrated clinical and genetic analysis of ABCA4-RD in AA patients. We will test the

central hypothesis that, as in our previous studies in European patients, a combination of advanced genetic

screening coupled with quantitative clinical data and functional analyses of ABCA4 alleles from both coding

and non-coding sequences from the entire ABCA4 locus is necessary to unequivocally determine the ABCA4-

RD structure in AA patients. This program represents a collaborative effort between five centers, with

demonstrated expertise in recruiting and comprehensive clinical characterization of patients, including cases of

AA descent, deciphering genetic causes of ABCA4-RD, and ABCA4 functional studies. The program is

organized into three Specific Aims. The first Aim is dedicated to patient recruitment and clinical analyses,

research in the second Aim identifies and analyzes all variants in the entire ABCA4 locus and exome, and

defines genotype-phenotype correlations, genetically defined disease subgroups and the entire structure of

ABCA4 variation in AA patients. The third Aim is dedicated to functional analyses of most frequent ABCA4

alleles in AA cases by testing for their effect in structural modeling, protein function in in vitro assays, mouse

models and iPS-derived retinal organoids. The proposed research will uncover and functionally verify the most

frequent ABCA4 disease-associated variants in AA patients, thereby substantially advancing precise disease

diagnosis, will refine clinical prognosis for ABCA4-RD caused by specific ABCA4 alleles, resulting in variable

age of disease onset, expression, and progression. Integrating clinical, genetic, and functional data in the

analyses and, eventually into a prediction matrix will improve diagnostic accuracy, prognostic counseling and

will provide a platform for designing precise phenotype-specific treatment in clinical trials for ABCA4-RD in

African Americans.

Grant Number: 5R01EY036061-02
NIH Institute/Center: NIH

Principal Investigator: RANDO ALLIKMETS

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →